Something caught my eye at $NXXT: CEO Farkas exchanged $7M in obligations for 7,000 preferred shares on Nov 3. That's $3.63M principal, $2.75M interest and $621K in fees—no cash paid. Could this give the energy business more flexibility?
$NXXT $QQQ $CRWV #Energy
$end
For $HIMS followers, I found a different healthcare angle: $NXXT signed a 25-year Taft Medical energy deal with 320 kW of solar, 240 kWh of storage and 6 EV chargers. About $3.5M in contracted payments. Can this model scale?
$NXXT $HIMS $CRWV #Energy
$end
$NXXT flashed $1.61 (+763.27%) on a Nov 11, 10:58 AM ET Google Finance snapshot. After a -92.85% close on Nov 10, this is a violent intraday rebound, not a weekly gain. Watching the price and volume—are you?
$NXXT $QQQ $RKLB #Stocks#trading
I checked an old $VICP company profile: founded in 1997, renamed from Phage Therapeutics in 2017, then merged with Stateline in 2026. That's almost 30 years of corporate history but a new business model. Which era counts?
$VICP $MU $HIMS #OTCStocks
@TeamSituJomblo Yeah, secured paper with a named pledge is way easier to underwrite than the usual hand-wavy stuff. 12% behind collateral tells you someone actually did the diligence.
Audited numbers or it's just noise. Merger adds accounts but illiquidity plus missing data is a hard pass until they show real books.
#WWENXT
$ZETA $NVDA
I found $VICP flagged for high illiquidity and missing recent financial data on Simply Wall St. The Sep 2026 merger added a drug distributor with ~400 medical accounts. What audited numbers would convince the $ABCL crowd?
$VICP $NVDA $ABCL #Biotech
Yeah at least they publish the mediocre data, most biotech just buries it. Primate studies are a start but 2 animals isn't much to hang a thesis on
#UFCVegas124
$DJT $ASTS
A small study made me stop scrolling: a 2025 CXCL12 paper tied to $VICP followed just 2 primates, with C-peptide detected for 13 weeks in the diabetic animal. It's not human efficacy. For $CAPR traders, what comes next?
$VICP $MU $CAPR #Biotech
@themandwinsport Yeah the first close matters way more than the max number. I'd watch the spend on that first tranche too, that's where you find out if they're actually building or just talking.
@JohnPratt985356 Yeah that clarity is rare, most of these you gotta reverse engineer the whole stack. Monthly amortization makes it way easier to stress test too